Gain Therapeutics Reports $5.3 Million Net Loss in Q3 2025, Seeks Additional Capital

Gain Therapeutics, Inc. reported a net loss of $5.3 million for the third quarter of 2025, compared to a loss of $4.5 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $15.6 million, a slight improvement from the $16.6 million loss reported for the same period in 2024. The increase in losses for the quarter was attributed to higher operating expenses, which rose to $4.8 million from $4.5 million year-over-year, driven primarily by increased research and development costs associated with ongoing clinical trials.

The company’s total operating expenses for the nine months ended September 30, 2025, were $14.2 million, down from $17 million in the previous year. This decrease was largely due to a reduction in research and development expenses, which fell to $7.9 million from $9.6 million, reflecting the recognition of research grant income and tax credits. General and administrative expenses also decreased to $6.4 million from $7.5 million, primarily due to lower stock-based compensation costs.

In terms of strategic developments, Gain Therapeutics has been actively advancing its clinical pipeline, particularly its lead product candidate, GT-02287, for the treatment of Parkinson’s disease. The company recently presented early results from its Phase 1b clinical study, indicating that the treatment was well tolerated with no serious adverse events reported. Additionally, the company extended the open-label study for an additional nine months, allowing participants to continue treatment, which reflects strong engagement and interest in the trial.

As of September 30, 2025, Gain Therapeutics had cash and cash equivalents totaling $8.8 million, a decrease from $10.4 million at the end of 2024. The company has incurred significant losses since its inception and has not yet generated revenue from product sales. The accumulated deficit increased to $96.8 million from $81.2 million year-over-year. The company anticipates needing additional capital to fund its operations beyond the first quarter of 2026, raising concerns about its ability to continue as a going concern without securing further financing.

Looking ahead, Gain Therapeutics plans to address its liquidity needs through a combination of public and private equity offerings, collaborations, and strategic partnerships. The company is also reviewing its cost structure to optimize expenditures and improve its cash burn rate. However, uncertainties in the macroeconomic environment, including geopolitical tensions and market volatility, may impact its ability to secure necessary funding.